ARIZONA
Study: MAX-1/Doxorubicin Combination Therapy for Doxorubicin Resistant Lymphoma in Dogs
Location: Southern Arizona Veterinary Specialty & Emergency Center, Tuscon, AZ
Phone: 1-877-762-9838 OR 520-888-3177
www.southernazvets.com/research-at-savsec.html
Summary: Study covers the cost of the doxorubicin drug costs and MAX-1. The owner remains responsible for visits,
laboratory work and administration costs
SOUTHERN CALIFORNIA
Study: A novel, non-chemotherapeutic agent designed specifically for canine B cell lymphoma
Location: Veterinary Cancer Group (Culver City, Woodland Hills, Tustin, San Diego)
Phone: 310.558.6120; 949.552.8274; 619.414.5056; 818.888.6882
www.vetcancergroup.com/media/3611/b-cell%20lymphoma%20trial%20facts.pdf
Purpose: To assess an advanced new therapy specifically designed to treat canine lymphoma. The primary goal of
the study is to measure the extension of survival time of cancer dogs treated with the novel therapy
when compared to untreated historical controls.
Background: Lymphoma is one of the most common blood cancers affecting dogs of different type of breeds and
ages. Lymphoma is a devastating disease that, when untreated, has a survival of 4-6 weeks. New treatment
options/additions are needed. The clinical trial treatment is not a chemotherapeutic agent. It is a product designed
specifically for canine lymphoma and has been shown in preliminary trials to be safe in dogs. This type of treatment has
been used for the treatment of lymphoma in humans. It improves survival in people when used in conjunction with
chemotherapy and was a groundbreaking advancement.
Eligibility: Newly diagnosed case of lymphoma. Adult dog of any breed preferably less than <40kg (80 lbs). Owner must
give written signed and dated consent to participate.
Treatment sequence:
Incentive: With the exception of first exam and consultation required to establish eligibility, this is a fully funded
study.
NORTHERN CALIFORNIA
Study: Preclinical evaluation of a novel synthetic antibody for treatment of spontaneously occurring
B-cell lymphoma in dogs.
Location: University of California Veterinary Hospital Davis, CA
Phone: 530.752.0125
www.vetmed.ucdavis.edu/vmth/small_animal/oncology/studies.cfm#lymphoma
Purpose: It is possible that treatment with SH 7139 will be an effective therapy for your dog’s lymphoma, and may result in
remission. It is hoped that with the information obtained from this trial, SH 7139 can proceed to clinical trials in people with
non-Hodgkin’s lymphoma.
Eligibility: The study will enroll adult dogs of any breed with peripheral lymphadenopathy, with confirmed B-cell lymphoma,
with a life expectancy of at least 6 weeks. This study intends to recruit both newly diagnosed cases without previous
treatment, and relapsed patients that may have failed other treatment options. All dogs must be examined by a VMTH
oncology or radiation oncology service veterinarian, and require the following baseline evaluations at the owners expense
before a dog can be considered for enrollment in the trial:
Owner’s Responsibilities: The owner will be responsible for scheduling appointments with the study coordinator and
keeping those appointments as required by protocol. Owners also have the responsibility to cover the cost of the initial
examination and blood work and any additional medications prescribed.
Financal Incentives: Dog owners participating in this study will be given special financial considerations. This is a fully
funded trial, once the patient is determined eligible by the oncologist. The study will pay for the cost of the weekly exam
fees, bloodwork, anti-body drug.
Study: Novel Product Targeting Canine B-Cell and T-Cell Lymphoma
Location: University of California Veterinary Hospital Davis, CA
Phone: 530.752.0125
www.vetmed.ucdavis.edu/vmth/small_animal/oncology/studies.cfm#lymphoma
Purpose: Lymphoma is one of the most common blood cancers affecting dogs of different type of breeds and ages.
Lymphoma is a devastating disease that, when left untreated, will lead to death in weeks. There is no cure known to this
disease. Current treatments involve the use of extensive chemotherapy and / or radiotherapy, resulting generally in an
initial response followed by relapse, and eventually resistance. Further, these treatments may be associated with severe
side effects affecting patient’s quality of life. Therefore, a more effective and safe treatment for canine lymphoma is
urgently needed.
New treatments based on the use of tumor targeting Product (non-chemotherapeutic agents) have been developed and
used for the treatment of lymphoma in humans achieving an improved treatment efficacy with survival extension and an
improved quality of life while significantly reducing toxicity. These treatments have proven to be groundbreaking for
humans.
This Product is designed specifically for dogs. This Product was shown to be safe in normal dogs and effective at depleting
lymphoma cells in laboratory studies. This study proposes the use of this Product to obtain additional data about its safety
and its Pharmacokinetic and Pharmacodynamic properties in dogs with lymphoma.
Eligibility: The study will enroll adult dogs of any breed with peripheral lymphadenopathy, with confirmed B-cell lymphoma
or T-Cell lymphoma, with a life expectancy of at least 6 weeks. This study intends to recruit both newly diagnosed cases
without previous treatment, and first relapsed.
Owner’s Responsibilities: The owner will be responsible for scheduling appointments with the study coordinator and
keeping those appointments as required by protocol. Owners also have the responsibility to cover the cost of the initial
examination and blood work and any additional medications prescribed.
Financal Incentives: Dog owners participating in this study will be given special financial considerations. The study will pay
for the cost of the Product, which is not available anywhere outside the study, and will also cover for the cost of
examination and blood work required by the study protocol after enrollment.
Study: Canine patients with Lymphoma or Oral Malignant Melanoma
Location: University of California Veterinary Hospital Davis, CA
Phone: 530.752.0125
www.vetmed.ucdavis.edu/vmth/small_animal/oncology/studies.cfm#lymphoma
Eligibility: Any prospective patient must be examined by the VMTH Oncology or Radiation Oncology service veterinarian,
and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the
trial:
• Confirmed diagnosis
• Physical examination with weight recorded
• CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it
was run at a commercial lab)
Baseline Evaluation for Eligibility:
• Histologically or cytologically confirmed disease
• Measurable and biopsiable tumor
• Ability to stay overnight
• Dog has to be greater than 10kg
• Informed owner consent
Purpose: The goal of this study is to evaluate the efficacy of using the enzyme Pegylated Arginine Deiminase (non-
chemotherapy drug) as a subcutaneous injection.
Financal Incentives: This study is fully funded.
COLORADO
Study: Liposomal clodronate to augment tumor vaccine responses in a canine model of non-Hodgkin
lymphoma.
Location: Colorado State University Animal Cancer Center, Fort Collins, CO
Phone: 970-297-4195
www.csuanimalcancercenter.org/vaccine-for-canine-lymphoma
Eligibility: Dogs with a confirmed diagnosis of stage IIIa or Iva, B-cell lymphoma are eligible for this study. Dogs must
undergo some diagnostic testing prior to starting the study to ensure that they are eligible, including bloodwork (complete
blood count and chemistry profile), thoracic radiographs, and flow cytometry to confirm B-cell immunophenotype. They
must have good function of liver and kidneys, have acceptable blood cell counts, and are free of severe underlying
disease. No prior chemotherapy for lymphoma is permitted, and a 14-day washout period from corticosteroids is required.
Summary: Mouse studies indicate that depletion of vaccine-elicited myeloid cells (VEMC) using liposomal clodronate
administered at the time of vaccination can significantly enhance tumor vaccine responses in mouse lymphoma models.
We have previously extensively evaluated liposomal clodronate as an antitumor drug in dogs with other types of cancer
(soft tissue sarcoma and malignant histiocytosis). We have also previously formulated autologous cancer vaccines and
administered them to dogs with lymphoma, melanoma and hemangiosarcoma, using a vaccine adjuvant developed in our
laboratory. We are now proposing to evaluate a combined tumor vaccine and VEMC depletion approach in dogs with B cell
lymphoma, as a model for human non-Hodgkin lymphoma.
The goals of this study are to determine whether co-administration of liposomal clodronate (LC) significantly improves
immune responses to a novel autologous lymphoma vaccine in dogs with B cell lymphoma, and to determine whether
effective vaccine responses can be generated in dogs undergoing concurrent chemotherapy for B cell lymphoma.
Requirements: The owner is responsible for the cost of diagnosing and staging the dog’s lymphoma prior to entering the
study. Owners are expected to make and keep all appointments according to the study protocol, and must be committed to
completing the entire study protocol and follow-up examinations.
Financial incentive: Clients participating in this study will be given special financial considerations. Specifically, the study
will cover the costs of the lymph node removal, recheck examinations, complete blood counts, and costs of chemotherapy
(drug and administration fees). The owner will be responsible for the costs of the initial examination, tests to insure
eligibility to participate, and any ancillary medications.The costs of treating any side effects related to chemotherapy will
also be the owner’s responsibility.
Study: Hydroxychloroquine to enhance doxorubicin effectiveness.
Location: Colorado State University Animal Cancer Center, Fort Collins, CO
Phone: 970-297-4195
www.csuanimalcancercenter.org/hydro-doxorubicin
Eligibility: Dogs with any type of measurable cancer are eligible for this study. Dogs must undergo some diagnostic testing
prior to starting the study to ensure that they are eligible (bloodwork, x-rays, +/- ultrasound, +/- tumor biopsy). They must
have good function of the liver and kidneys and acceptable blood cell counts. No concurrent cancer therapy can be given
during the study, and a 3-week washout from prior chemotherapy and 6-week washout from prior radiation therapy is
required. Owners must consent to a post-mortem examination (autopsy) at the time their pet dies or is euthanized.
Summary: This clinical trial is designed to evaluate a form of treatment for dogs with cancer using a combination of the
antimalarial drug hydroxychloroquine (HCQ) and the chemotherapy agent doxorubicin (DOX). Recent studies suggest that
HCQ can sensitize human tumor cells to the anti-cancer effect of DOX. Recent studies in dogs with skin disease have
demonstrated that long-term HCQ treatment appears to be well-tolerated. The combination of these two treatments has
not been explored in canine cancer patients. The goal of this study is to determine the maximum tolerated dose of HCQ
that can be administered to tumor-bearing dogs when followed by a standard dose of DOX.
Requirements: The owner is responsible for scheduling appointments with the oncology clinical trials coordinator and
keeping those appointments as required by study protocol. The owner is responsible for the costs of diagnosis and staging
of the tumor prior to entering the study.
Financial incentive: Clients participating in this study will be given special financial considerations. Specifically, the study
will pay for many of the costs associated with the study, including recheck examinations, tumor biopsies for the study, and
study-related blood tests. The HCQ and DOX are also provided at no cost. The costs of DOX administration and recheck
imaging tests such as x-rays or ultrasound, if necessary to determine treatment effectiveness, are the responsibility of the
owners.
INDIANA
Location: Purdue University Veterinary School of Medicine, West Lafayette, IN
Contact information: Dr. Michael Childress at (765) 494-1107 or mochildr@purdue.edu, or you may contact Sarah
Lahrman at (765) 496-6289 or salahrma@purdue.edu
www.vet.purdue.edu/pcop/LymphomaWebContent.pdf
Study: Influence of Prednisone on Remission and P-glycoprotein expression in Dogs with Lymphoma
Summary: Prednisone is one of the most commonly used drugs in chemotherapy protocols for lymphoma, and has been
used to treat lymphoma for decades. Recently, however, questions have been raised as to whether prednisone could have
any detrimental effects in the treatment of lymphoma. Previous studies have demonstrated that treatment with prednisone
before starting a combination chemotherapy protocol is associated with a shorter duration of remission, decreased survival
time, and increased risk of the cancer being resistant to chemotherapy. It is thought that this less favorable outcome is due
to prednisone causing chemotherapeutic drug resistance. It is not currently known if prednisone therapy has any adverse
effects when started at the time that chemotherapy is initiated. It is also not known whether the incorporation of prednisone
into a multi-drug protocol for lymphoma is more often beneficial or detrimental. The purpose of this clinical trial is to assess
the importance of prednisone in a combination chemotherapy protocol (UW-25) for canine lymphoma. Dogs entering into
this trial will be randomly assigned to receive either the standard UW-25 protocol (the current standard of care for canine
lymphoma that does include prednisone) or a modified UW-25 protocol that does not include prednisone. Dogs will be
eligible for the clinical trial if they have a biopsy diagnosis of multicentric lymphoma and have received no prior
chemotherapy or radiation therapy treatment within the past 30 days. They must also not have received previous treatment
with prednisone or other steroid drugs such as dexamethasone or Depo-medrol within the past 30 days.
Financial Incentve: Financial benefit will be provided for owners of dogs enrolling in the clinical trial. The treatment for dogs
in the trial will cost approximately 10% less than it would otherwise. For instance, if treating your dog would normally cost
$5000, a discount of approximately $500 will be applied to your dog’s treatment.
LOUISIANA
Study: Mitoxantrone versus Mitoxantrone + DTIC for dogs with refractory lymphoma who were
previously treated with chemotherapy
Location: Louisiana State University School of Veterinary Medicine, Baton Rouge, LA 70803
Phone: 225-578-9600
www.vetmed.lsu.edu/clinical_trials.htm
Eligibility: To be eligible for this study, your dog must meet the following criteria: confirmed diagnosis of lymphoma;
relapsed after initial treatment with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone), must
have never received mitoxantrone or DTIC chemotherapy and has not had chemotherapy for 14 days prior to initiating this
treatment.
Summary: The purpose of this study is to compare the efficacy of single-agent mitoxantrone to the combination of
mitoxantrone and DTIC, in dogs with CHOP-resistant lymphoma.
MASSACHUSETTS
Study: High-dose cyclophosphamide for dogs with previously treated lymphoma
Location: Tufts University Cummings School of Veterinary Medicine, North Grafton, MA
Phone: Kelly Reed, Oncology Liaison; (508) 887-4682
http://cgi.vet.tufts.edu/clinical_trials/projects/highdose_cyclophosphamide_for_canine_lymphoma
Eligibility: Dogs with multicentric lymphoma in complete remission after multiagent CHOP-based induction chemotherapy.
Dogs with other significant medical conditions or who lower urinary tract disease are ineligible to participate in this study.
Summary: Although canine lymphoma is highly responsive to chemotherapy, the disease is rarely cured since the disease
recurs in most dogs that receive chemotherapy. The goal of this study is to determine the highest dose of
cyclophosphamide that can be given safely with cytokine support and whether this treatment will prolong remission duration
beyond standard chemotherapy protocols.
Requirement and incentive: Dog owners are financially responsible for costs associated with standard chemotherapy.
Additionally the owner may be financially responsible for all tests that determine if the patient qualifies for the study. These
tests may include re-check examination fees, blood and urine tests. This study covers the cost associated with high-dose
cyclophosphamide treatment, monitoring and supportive care.
Other studies that do not evaluate a novel treatment but help oncologists gain a deeper understanding of the disease that
might help develop new treatments in the future:
MINNESOTA
Study: LICKing Lymphoma: Ablation of tumor initiating cells by P-glycoprotein inhibition: Proof of
principle study in canine diffuse large B-cell lymphoma
Location: University of Minnesota Veterinary Medical Center
Contact: Amber Winter, study technician 612-624-1352 or alwinter@umn.edu
www.cvm.umn.edu/cic/current/oncology/home.html#LL
Eligibility:
•body weight > 15kg (33 lbs) and < 50 kg (110 lbs)
•have not started chemotherapy or corticosteroids
•have adequate platelets (>= 100,000/ml)
•have adequate supply of blood cells (>= 30% packed cell volume)
•have no concurrent renal or hepatic disease, congestive heart failure or clinical coagulopathy
Excluded dog breeds due to special concerns: Rough and soft-coated collies, Shetland sheepdogs, Australian shepherds,
boxers, Siberian huskies and Alaskan malamutes
Summary: We are looking for dogs recently diagnosed with or highly suspected of having lymphoma. The purpose of this
study is to determine if the addition of an experimental drug with chemotherapy may reduce or eliminate tumor-initiating
cells by increasing their sensitivity to conventional chemotherapy.
Requirement and incentive: Owners will elect conventional chemotherapy and be responsible for the screening
appointment. Once enrolled, the study covers the cost of the study drug or placebo, biopsies, blood sampling and
subsequent chemotherapy up to a maximum of $2500.
Study: OSAL: Safety and Tumor Response of Salmonella-IL12 in Combination wiht Adriamycin and in
Dogs with Appendicular Osteosarcoma
Location: University of Minnesota Veterinary Medical Center
Contact: Sara Pracht at 612-626-3574 or prach011@umn.edu, or 612-626-8387
www.cvm.umn.edu/cic/current/oncology/home.html#OSAL
Eligibility: Patients for this study will be otherwise healthy, with OSA limited to one limb, whose owners are willing pursue the
standard treatments of amputation and chemotherapy. We are looking for new cases, those that have not yet had surgery,
chemotherapy or radiation treatments. In addition, patients will need to have a negative stool culture for Salmonella and
not be on a raw diet.
Summary: Osteosarcoma (OSA) is the most common bone tumor found in the dog. In approximately 90% of dogs with OSA,
the cancer has already spread by the time they are diagnosed. With surgery alone, dogs have a median survival of 3-4
months which increases to 9-14 months with chemotherapy. We are studying the use of an attenuated strain of Salmonella
typhimurium conjugated to the IL2 gene (Salmonella IL2) in addition to standard of care in treating dogs with
osteosarcoma. Salmonella-IL2 has been shown to be safe and to reduce tumor volume (size) in various animal species.
There is an on-going early clinical trial in human patients with no toxicities noted thus far.
PET-CT: Some of the patients enrolled in the study will be asked to let us perform PET-CT imaging. Positron Emission
Tomography/ Computed Tomography is a special kind of imaging that allows us to assess metastasis or spread of the
cancer. If the owner agrees, we will transport the patient to an imaging center on the Minneapolis campus at the beginning
of the study and after 6 months of treatment.
Requirement and incentive: The study will cover costs from Day 1 on, including PET-CT, up to $2,000. Owners will be
responsible for the prescreening/staging visit and costs beyond this amount.
MISSOURI
Study: Artemisinin-LSA study
Location: University of Missouri, Columbia, MO
Phone: 573-882-7821
www.cvm.missouri.edu/oncology/current.html
Eligibility:
Overview: The purpose of this study is to evaluate the ability of artemisinin to down regulate genes that cause resistance
to chemotherapy, and evaluate response to doxorubicin chemotherapy and artemisinin together as compared to a
doxorubicin/placebo combination.
Protocol Overview:
Incentives: Once enrolled study is fully funded. Treatment includes: Sample collection, free drug and drug administration,
blood work, re-evaluating disease burden and office calls. Owner is responsible for diagnosis and staging, if accepted into
the study owner will only pay first $300.00 of staging.
Study: Bcl-2 Canine Lymphoma Study
Location: University of Missouri, Columbia, MO
Phone: 573-882-7821 (Dr.’s Sandra Axiak and Mike Lewis)
www.cvm.missouri.edu/oncology/current.html
Eligibility:
Overview: Bcl-2 Canine Lymphoma Study is an imaging study that involves injection of a radioisotope (indium) to detect the
presence of the bcl-2 gene product inside tumor cells of canines with B cell lymphoma. Patients will receive three separate
scans…one at enrollment; another after the patient has been in a durable remission (6-8 week range) and one at relapse.
All dogs participating in this study will be placed on the University of Wisconsin-Madison lymphoma protocol. This 25 week
protocol is considered the gold standard for treating canine lymphoma.
Protocol Overview:
Incentives: Owner to pay $500.00 of initial staging, all nuclear medicine scans, chemotherapy and blood work cost are
covered by the study.
PENNSYLVANIA
Study: Evaluation of NBD Peptide as an Adjunct Therapy for the Treatment of Non-Hodgkin Lymphoma
Location: University of Pennsylvania Veterinary Hospital, Philadelphia, PA
If you are interested in learning more about this study, please contact the VCIC at 215-573-0302 or vcic@vet.upenn.edu
http://research.vet.upenn.edu/ClinicalStudies/CanineLymphoma/tabid/4518/articleType/ArticleView/articleId/31/New-
Treatment-for-Canine-Lymphoma.aspx
Eligibility:
Your dog is eligible to participate in this clinical trial if:
Your dog is not eligible to participate in this study if :
Summary: Lymphoma is a cancer of white blood cells that occurs commonly in dogs. Chemotherapy is used to treat
lymphoma and about 85% of dogs respond well to this treatment. However, the majority of dogs will relapse with clinical
disease within one year of diagnosis and treatment. One potential reason for disease recurrence is the presence of drug
resistant lymphoma cells that are not killed by chemotherapy. Researchers at Penn Vet have identified an aberrantly
active, intracellular pathway within lymphoma cells that promotes cancer cell survival and proliferation. Results of a pilot
clinical trial have shown that blocking this pathway using a drug known as NBD peptide can promote cancerous cell death.
This clinical trial expands on our previous pilot study and aims to determine whether NBD peptide can inhibit aberrant
pathway activity and kill cancer cells in dogs with B-cell lymphoma improve short and long term outcomes in dogs with
lymphoma.
Benefits: There is no fee to participate in this study. All study procedures (including blood work and lymphoma
immunophenotyping) plus study medication (NBD peptide and antibiotics) will be provided at no cost. The study will pay for
a single dose of standard chemotherapy. The potential benefits could include increased responsiveness to chemotherapy
leading to remission and prolonged remission times in patients receiving the NBD peptide.
WISCONSIN
Study: Dogs with T-cell lymphoma
Location: University of Wisconsin Veterinary Teaching Hospital, Madison, WI
Phone: (608) 263-7600
www.uwveterinarycare.wisc.edu/rdvm/clinical_trials.html
Summary: Lymphoma is one of the most common cancers in dogs. Most affected dogs present with enlarged lymph
nodes. While lymphoma is responsive to chemotherapy, with more than 80% of dogs achieving complete clinical remission
of more than one year, the type of cell involved (T-cell or B-cell) affects prognosis. Dogs with T-cell lymphoma have a
poorer prognosis as these cells are more resistant to chemotherapy and remission times are shorter than for dogs with B-
cell involvement. Recent laboratory observations suggest that the tyrosine kinase inhibitor, masitinib (discussed above
under Malignant Melanoma) may enhance the anti-tumor activity of chemotherapeutic agents. Dogs with confirmed T-cell
lymphoma will be eligible for this study and will be randomized to receive either masitinib alone, doxorubicin alone, or a
combination of these agents. The cost of masitinib and doxorubicin will be paid for by the study. Owners are responsible
for the cost of the initial staging (approximately $400-600), blood and urine tests, and examination fees.
Study: MAX-1/Doxorubicin Combination Therapy for Doxorubicin Resistant Lymphoma in Dogs
Location: Southern Arizona Veterinary Specialty & Emergency Center, Tuscon, AZ
Phone: 1-877-762-9838 OR 520-888-3177
www.southernazvets.com/research-at-savsec.html
Summary: Study covers the cost of the doxorubicin drug costs and MAX-1. The owner remains responsible for visits,
laboratory work and administration costs
SOUTHERN CALIFORNIA
Study: A novel, non-chemotherapeutic agent designed specifically for canine B cell lymphoma
Location: Veterinary Cancer Group (Culver City, Woodland Hills, Tustin, San Diego)
Phone: 310.558.6120; 949.552.8274; 619.414.5056; 818.888.6882
www.vetcancergroup.com/media/3611/b-cell%20lymphoma%20trial%20facts.pdf
Purpose: To assess an advanced new therapy specifically designed to treat canine lymphoma. The primary goal of
the study is to measure the extension of survival time of cancer dogs treated with the novel therapy
when compared to untreated historical controls.
Background: Lymphoma is one of the most common blood cancers affecting dogs of different type of breeds and
ages. Lymphoma is a devastating disease that, when untreated, has a survival of 4-6 weeks. New treatment
options/additions are needed. The clinical trial treatment is not a chemotherapeutic agent. It is a product designed
specifically for canine lymphoma and has been shown in preliminary trials to be safe in dogs. This type of treatment has
been used for the treatment of lymphoma in humans. It improves survival in people when used in conjunction with
chemotherapy and was a groundbreaking advancement.
Eligibility: Newly diagnosed case of lymphoma. Adult dog of any breed preferably less than <40kg (80 lbs). Owner must
give written signed and dated consent to participate.
Treatment sequence:
- Candidates are evaluated and confirmed to meet the inclusion criteria by undergoing a complete physical
examination, lymph node assessment, body weight, blood sample for lymphocyte level, CBC/Chemistry/Urinalysis,
and fine needle aspiration. - Patients will then begin to receive intravenous injections of the new product for 8 weeks.
- Patients will be closely monitored throughout the treatment process.
Incentive: With the exception of first exam and consultation required to establish eligibility, this is a fully funded
study.
NORTHERN CALIFORNIA
Study: Preclinical evaluation of a novel synthetic antibody for treatment of spontaneously occurring
B-cell lymphoma in dogs.
Location: University of California Veterinary Hospital Davis, CA
Phone: 530.752.0125
www.vetmed.ucdavis.edu/vmth/small_animal/oncology/studies.cfm#lymphoma
Purpose: It is possible that treatment with SH 7139 will be an effective therapy for your dog’s lymphoma, and may result in
remission. It is hoped that with the information obtained from this trial, SH 7139 can proceed to clinical trials in people with
non-Hodgkin’s lymphoma.
Eligibility: The study will enroll adult dogs of any breed with peripheral lymphadenopathy, with confirmed B-cell lymphoma,
with a life expectancy of at least 6 weeks. This study intends to recruit both newly diagnosed cases without previous
treatment, and relapsed patients that may have failed other treatment options. All dogs must be examined by a VMTH
oncology or radiation oncology service veterinarian, and require the following baseline evaluations at the owners expense
before a dog can be considered for enrollment in the trial:
- Confirmed diagnosis
- Physical examination with weight recorded
- CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long
as it was ran at a commercial lab) - Histologically or cytologically confirmed disease
- At least one measurable affected organ
- Informed owner consent
Owner’s Responsibilities: The owner will be responsible for scheduling appointments with the study coordinator and
keeping those appointments as required by protocol. Owners also have the responsibility to cover the cost of the initial
examination and blood work and any additional medications prescribed.
Financal Incentives: Dog owners participating in this study will be given special financial considerations. This is a fully
funded trial, once the patient is determined eligible by the oncologist. The study will pay for the cost of the weekly exam
fees, bloodwork, anti-body drug.
Study: Novel Product Targeting Canine B-Cell and T-Cell Lymphoma
Location: University of California Veterinary Hospital Davis, CA
Phone: 530.752.0125
www.vetmed.ucdavis.edu/vmth/small_animal/oncology/studies.cfm#lymphoma
Purpose: Lymphoma is one of the most common blood cancers affecting dogs of different type of breeds and ages.
Lymphoma is a devastating disease that, when left untreated, will lead to death in weeks. There is no cure known to this
disease. Current treatments involve the use of extensive chemotherapy and / or radiotherapy, resulting generally in an
initial response followed by relapse, and eventually resistance. Further, these treatments may be associated with severe
side effects affecting patient’s quality of life. Therefore, a more effective and safe treatment for canine lymphoma is
urgently needed.
New treatments based on the use of tumor targeting Product (non-chemotherapeutic agents) have been developed and
used for the treatment of lymphoma in humans achieving an improved treatment efficacy with survival extension and an
improved quality of life while significantly reducing toxicity. These treatments have proven to be groundbreaking for
humans.
This Product is designed specifically for dogs. This Product was shown to be safe in normal dogs and effective at depleting
lymphoma cells in laboratory studies. This study proposes the use of this Product to obtain additional data about its safety
and its Pharmacokinetic and Pharmacodynamic properties in dogs with lymphoma.
Eligibility: The study will enroll adult dogs of any breed with peripheral lymphadenopathy, with confirmed B-cell lymphoma
or T-Cell lymphoma, with a life expectancy of at least 6 weeks. This study intends to recruit both newly diagnosed cases
without previous treatment, and first relapsed.
Owner’s Responsibilities: The owner will be responsible for scheduling appointments with the study coordinator and
keeping those appointments as required by protocol. Owners also have the responsibility to cover the cost of the initial
examination and blood work and any additional medications prescribed.
Financal Incentives: Dog owners participating in this study will be given special financial considerations. The study will pay
for the cost of the Product, which is not available anywhere outside the study, and will also cover for the cost of
examination and blood work required by the study protocol after enrollment.
Study: Canine patients with Lymphoma or Oral Malignant Melanoma
Location: University of California Veterinary Hospital Davis, CA
Phone: 530.752.0125
www.vetmed.ucdavis.edu/vmth/small_animal/oncology/studies.cfm#lymphoma
Eligibility: Any prospective patient must be examined by the VMTH Oncology or Radiation Oncology service veterinarian,
and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the
trial:
• Confirmed diagnosis
• Physical examination with weight recorded
• CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it
was run at a commercial lab)
Baseline Evaluation for Eligibility:
• Histologically or cytologically confirmed disease
• Measurable and biopsiable tumor
• Ability to stay overnight
• Dog has to be greater than 10kg
• Informed owner consent
Purpose: The goal of this study is to evaluate the efficacy of using the enzyme Pegylated Arginine Deiminase (non-
chemotherapy drug) as a subcutaneous injection.
Financal Incentives: This study is fully funded.
COLORADO
Study: Liposomal clodronate to augment tumor vaccine responses in a canine model of non-Hodgkin
lymphoma.
Location: Colorado State University Animal Cancer Center, Fort Collins, CO
Phone: 970-297-4195
www.csuanimalcancercenter.org/vaccine-for-canine-lymphoma
Eligibility: Dogs with a confirmed diagnosis of stage IIIa or Iva, B-cell lymphoma are eligible for this study. Dogs must
undergo some diagnostic testing prior to starting the study to ensure that they are eligible, including bloodwork (complete
blood count and chemistry profile), thoracic radiographs, and flow cytometry to confirm B-cell immunophenotype. They
must have good function of liver and kidneys, have acceptable blood cell counts, and are free of severe underlying
disease. No prior chemotherapy for lymphoma is permitted, and a 14-day washout period from corticosteroids is required.
Summary: Mouse studies indicate that depletion of vaccine-elicited myeloid cells (VEMC) using liposomal clodronate
administered at the time of vaccination can significantly enhance tumor vaccine responses in mouse lymphoma models.
We have previously extensively evaluated liposomal clodronate as an antitumor drug in dogs with other types of cancer
(soft tissue sarcoma and malignant histiocytosis). We have also previously formulated autologous cancer vaccines and
administered them to dogs with lymphoma, melanoma and hemangiosarcoma, using a vaccine adjuvant developed in our
laboratory. We are now proposing to evaluate a combined tumor vaccine and VEMC depletion approach in dogs with B cell
lymphoma, as a model for human non-Hodgkin lymphoma.
The goals of this study are to determine whether co-administration of liposomal clodronate (LC) significantly improves
immune responses to a novel autologous lymphoma vaccine in dogs with B cell lymphoma, and to determine whether
effective vaccine responses can be generated in dogs undergoing concurrent chemotherapy for B cell lymphoma.
Requirements: The owner is responsible for the cost of diagnosing and staging the dog’s lymphoma prior to entering the
study. Owners are expected to make and keep all appointments according to the study protocol, and must be committed to
completing the entire study protocol and follow-up examinations.
Financial incentive: Clients participating in this study will be given special financial considerations. Specifically, the study
will cover the costs of the lymph node removal, recheck examinations, complete blood counts, and costs of chemotherapy
(drug and administration fees). The owner will be responsible for the costs of the initial examination, tests to insure
eligibility to participate, and any ancillary medications.The costs of treating any side effects related to chemotherapy will
also be the owner’s responsibility.
Study: Hydroxychloroquine to enhance doxorubicin effectiveness.
Location: Colorado State University Animal Cancer Center, Fort Collins, CO
Phone: 970-297-4195
www.csuanimalcancercenter.org/hydro-doxorubicin
Eligibility: Dogs with any type of measurable cancer are eligible for this study. Dogs must undergo some diagnostic testing
prior to starting the study to ensure that they are eligible (bloodwork, x-rays, +/- ultrasound, +/- tumor biopsy). They must
have good function of the liver and kidneys and acceptable blood cell counts. No concurrent cancer therapy can be given
during the study, and a 3-week washout from prior chemotherapy and 6-week washout from prior radiation therapy is
required. Owners must consent to a post-mortem examination (autopsy) at the time their pet dies or is euthanized.
Summary: This clinical trial is designed to evaluate a form of treatment for dogs with cancer using a combination of the
antimalarial drug hydroxychloroquine (HCQ) and the chemotherapy agent doxorubicin (DOX). Recent studies suggest that
HCQ can sensitize human tumor cells to the anti-cancer effect of DOX. Recent studies in dogs with skin disease have
demonstrated that long-term HCQ treatment appears to be well-tolerated. The combination of these two treatments has
not been explored in canine cancer patients. The goal of this study is to determine the maximum tolerated dose of HCQ
that can be administered to tumor-bearing dogs when followed by a standard dose of DOX.
Requirements: The owner is responsible for scheduling appointments with the oncology clinical trials coordinator and
keeping those appointments as required by study protocol. The owner is responsible for the costs of diagnosis and staging
of the tumor prior to entering the study.
Financial incentive: Clients participating in this study will be given special financial considerations. Specifically, the study
will pay for many of the costs associated with the study, including recheck examinations, tumor biopsies for the study, and
study-related blood tests. The HCQ and DOX are also provided at no cost. The costs of DOX administration and recheck
imaging tests such as x-rays or ultrasound, if necessary to determine treatment effectiveness, are the responsibility of the
owners.
INDIANA
Location: Purdue University Veterinary School of Medicine, West Lafayette, IN
Contact information: Dr. Michael Childress at (765) 494-1107 or mochildr@purdue.edu, or you may contact Sarah
Lahrman at (765) 496-6289 or salahrma@purdue.edu
www.vet.purdue.edu/pcop/LymphomaWebContent.pdf
Study: Influence of Prednisone on Remission and P-glycoprotein expression in Dogs with Lymphoma
Summary: Prednisone is one of the most commonly used drugs in chemotherapy protocols for lymphoma, and has been
used to treat lymphoma for decades. Recently, however, questions have been raised as to whether prednisone could have
any detrimental effects in the treatment of lymphoma. Previous studies have demonstrated that treatment with prednisone
before starting a combination chemotherapy protocol is associated with a shorter duration of remission, decreased survival
time, and increased risk of the cancer being resistant to chemotherapy. It is thought that this less favorable outcome is due
to prednisone causing chemotherapeutic drug resistance. It is not currently known if prednisone therapy has any adverse
effects when started at the time that chemotherapy is initiated. It is also not known whether the incorporation of prednisone
into a multi-drug protocol for lymphoma is more often beneficial or detrimental. The purpose of this clinical trial is to assess
the importance of prednisone in a combination chemotherapy protocol (UW-25) for canine lymphoma. Dogs entering into
this trial will be randomly assigned to receive either the standard UW-25 protocol (the current standard of care for canine
lymphoma that does include prednisone) or a modified UW-25 protocol that does not include prednisone. Dogs will be
eligible for the clinical trial if they have a biopsy diagnosis of multicentric lymphoma and have received no prior
chemotherapy or radiation therapy treatment within the past 30 days. They must also not have received previous treatment
with prednisone or other steroid drugs such as dexamethasone or Depo-medrol within the past 30 days.
Financial Incentve: Financial benefit will be provided for owners of dogs enrolling in the clinical trial. The treatment for dogs
in the trial will cost approximately 10% less than it would otherwise. For instance, if treating your dog would normally cost
$5000, a discount of approximately $500 will be applied to your dog’s treatment.
LOUISIANA
Study: Mitoxantrone versus Mitoxantrone + DTIC for dogs with refractory lymphoma who were
previously treated with chemotherapy
Location: Louisiana State University School of Veterinary Medicine, Baton Rouge, LA 70803
Phone: 225-578-9600
www.vetmed.lsu.edu/clinical_trials.htm
Eligibility: To be eligible for this study, your dog must meet the following criteria: confirmed diagnosis of lymphoma;
relapsed after initial treatment with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone), must
have never received mitoxantrone or DTIC chemotherapy and has not had chemotherapy for 14 days prior to initiating this
treatment.
Summary: The purpose of this study is to compare the efficacy of single-agent mitoxantrone to the combination of
mitoxantrone and DTIC, in dogs with CHOP-resistant lymphoma.
MASSACHUSETTS
Study: High-dose cyclophosphamide for dogs with previously treated lymphoma
Location: Tufts University Cummings School of Veterinary Medicine, North Grafton, MA
Phone: Kelly Reed, Oncology Liaison; (508) 887-4682
http://cgi.vet.tufts.edu/clinical_trials/projects/highdose_cyclophosphamide_for_canine_lymphoma
Eligibility: Dogs with multicentric lymphoma in complete remission after multiagent CHOP-based induction chemotherapy.
Dogs with other significant medical conditions or who lower urinary tract disease are ineligible to participate in this study.
Summary: Although canine lymphoma is highly responsive to chemotherapy, the disease is rarely cured since the disease
recurs in most dogs that receive chemotherapy. The goal of this study is to determine the highest dose of
cyclophosphamide that can be given safely with cytokine support and whether this treatment will prolong remission duration
beyond standard chemotherapy protocols.
Requirement and incentive: Dog owners are financially responsible for costs associated with standard chemotherapy.
Additionally the owner may be financially responsible for all tests that determine if the patient qualifies for the study. These
tests may include re-check examination fees, blood and urine tests. This study covers the cost associated with high-dose
cyclophosphamide treatment, monitoring and supportive care.
Other studies that do not evaluate a novel treatment but help oncologists gain a deeper understanding of the disease that
might help develop new treatments in the future:
- Body Condition in Canine Lymphoma
- Histologic and Cytogenetic Analysis of Canine Lymphoma
- Determination of ABCB1 (MDR1) Expression in Relapsed Lymphoma
MINNESOTA
Study: LICKing Lymphoma: Ablation of tumor initiating cells by P-glycoprotein inhibition: Proof of
principle study in canine diffuse large B-cell lymphoma
Location: University of Minnesota Veterinary Medical Center
Contact: Amber Winter, study technician 612-624-1352 or alwinter@umn.edu
www.cvm.umn.edu/cic/current/oncology/home.html#LL
Eligibility:
•body weight > 15kg (33 lbs) and < 50 kg (110 lbs)
•have not started chemotherapy or corticosteroids
•have adequate platelets (>= 100,000/ml)
•have adequate supply of blood cells (>= 30% packed cell volume)
•have no concurrent renal or hepatic disease, congestive heart failure or clinical coagulopathy
Excluded dog breeds due to special concerns: Rough and soft-coated collies, Shetland sheepdogs, Australian shepherds,
boxers, Siberian huskies and Alaskan malamutes
Summary: We are looking for dogs recently diagnosed with or highly suspected of having lymphoma. The purpose of this
study is to determine if the addition of an experimental drug with chemotherapy may reduce or eliminate tumor-initiating
cells by increasing their sensitivity to conventional chemotherapy.
Requirement and incentive: Owners will elect conventional chemotherapy and be responsible for the screening
appointment. Once enrolled, the study covers the cost of the study drug or placebo, biopsies, blood sampling and
subsequent chemotherapy up to a maximum of $2500.
Study: OSAL: Safety and Tumor Response of Salmonella-IL12 in Combination wiht Adriamycin and in
Dogs with Appendicular Osteosarcoma
Location: University of Minnesota Veterinary Medical Center
Contact: Sara Pracht at 612-626-3574 or prach011@umn.edu, or 612-626-8387
www.cvm.umn.edu/cic/current/oncology/home.html#OSAL
Eligibility: Patients for this study will be otherwise healthy, with OSA limited to one limb, whose owners are willing pursue the
standard treatments of amputation and chemotherapy. We are looking for new cases, those that have not yet had surgery,
chemotherapy or radiation treatments. In addition, patients will need to have a negative stool culture for Salmonella and
not be on a raw diet.
Summary: Osteosarcoma (OSA) is the most common bone tumor found in the dog. In approximately 90% of dogs with OSA,
the cancer has already spread by the time they are diagnosed. With surgery alone, dogs have a median survival of 3-4
months which increases to 9-14 months with chemotherapy. We are studying the use of an attenuated strain of Salmonella
typhimurium conjugated to the IL2 gene (Salmonella IL2) in addition to standard of care in treating dogs with
osteosarcoma. Salmonella-IL2 has been shown to be safe and to reduce tumor volume (size) in various animal species.
There is an on-going early clinical trial in human patients with no toxicities noted thus far.
PET-CT: Some of the patients enrolled in the study will be asked to let us perform PET-CT imaging. Positron Emission
Tomography/ Computed Tomography is a special kind of imaging that allows us to assess metastasis or spread of the
cancer. If the owner agrees, we will transport the patient to an imaging center on the Minneapolis campus at the beginning
of the study and after 6 months of treatment.
Requirement and incentive: The study will cover costs from Day 1 on, including PET-CT, up to $2,000. Owners will be
responsible for the prescreening/staging visit and costs beyond this amount.
MISSOURI
Study: Artemisinin-LSA study
Location: University of Missouri, Columbia, MO
Phone: 573-882-7821
www.cvm.missouri.edu/oncology/current.html
Eligibility:
- Confirmed B cell multicentric, Stage IIIa or IVa lymphoma
- Complete staging including CBC, chemistry panel, flow cytometry, abdominal U/S, BMA, study echo and thoracic
radiographs at first visit. - No previous chemotherapy including prednisone.
- No cardiac, renal or hepatic insufficiency
- Owners must consent to a necropsy if patients dies or is euthanized during course of the study.
- Patients will undergo two separate lymph node biopsies, one prior to artemisinin or placebo administration and
another three days later. - Owners are expected to keep a drug log to record administration for duration of the study
Overview: The purpose of this study is to evaluate the ability of artemisinin to down regulate genes that cause resistance
to chemotherapy, and evaluate response to doxorubicin chemotherapy and artemisinin together as compared to a
doxorubicin/placebo combination.
Protocol Overview:
- Twice daily oral medication of either artemisinin or placebo for the duration of the study
- Doxorubicin (30mg/m2) every 3 weeks for a total of three treatments.
- CBC prior to and one week after each scheduled chemotherapy
- Monthly rechecks for the duration of the study.
Incentives: Once enrolled study is fully funded. Treatment includes: Sample collection, free drug and drug administration,
blood work, re-evaluating disease burden and office calls. Owner is responsible for diagnosis and staging, if accepted into
the study owner will only pay first $300.00 of staging.
Study: Bcl-2 Canine Lymphoma Study
Location: University of Missouri, Columbia, MO
Phone: 573-882-7821 (Dr.’s Sandra Axiak and Mike Lewis)
www.cvm.missouri.edu/oncology/current.html
Eligibility:
- B Cell lymphoma confirmed by histopathology
- Complete tumor staging including: CBC, chemistry panel, UA, thoracic radiographs, abdominal radiographs+ US,
bone marrow aspirate and lymph node biopsy. - Life expectancy of > 12 weeks, NO previous chemo other than prednisone for < 2 weeks. Adequate renal, hepatic
and hematopoietic perimeters. - Exclusion criteria: hypercalcemia and mediastinal lymph node involvement
Overview: Bcl-2 Canine Lymphoma Study is an imaging study that involves injection of a radioisotope (indium) to detect the
presence of the bcl-2 gene product inside tumor cells of canines with B cell lymphoma. Patients will receive three separate
scans…one at enrollment; another after the patient has been in a durable remission (6-8 week range) and one at relapse.
All dogs participating in this study will be placed on the University of Wisconsin-Madison lymphoma protocol. This 25 week
protocol is considered the gold standard for treating canine lymphoma.
Protocol Overview:
- Two nuclear medicine (indium) scans- one at enrollment, one after a durable remission (6-8 weeks).
- University of Wisconsin-Madison lymphoma protocol
Incentives: Owner to pay $500.00 of initial staging, all nuclear medicine scans, chemotherapy and blood work cost are
covered by the study.
PENNSYLVANIA
Study: Evaluation of NBD Peptide as an Adjunct Therapy for the Treatment of Non-Hodgkin Lymphoma
Location: University of Pennsylvania Veterinary Hospital, Philadelphia, PA
If you are interested in learning more about this study, please contact the VCIC at 215-573-0302 or vcic@vet.upenn.edu
http://research.vet.upenn.edu/ClinicalStudies/CanineLymphoma/tabid/4518/articleType/ArticleView/articleId/31/New-
Treatment-for-Canine-Lymphoma.aspx
Eligibility:
Your dog is eligible to participate in this clinical trial if:
- They have been diagnosed with diffuse large B-cell lymphoma
- They have relapsed with the disease OR are newly diagnosed
- If the dog is relapsed, they have not received chemotherapy at least 3 weeks prior to screening. If newly diagnosed,
they have not yet received any chemotherapy treatment - They have NOT received prednisone or other systemic steroids within the past three weeks
- They are otherwise healthy with no major organ disease
- They have evidence of an active NF-kappaB pathway within their malignant lymph node (to be determined at
screening visit)
Your dog is not eligible to participate in this study if :
- They have T cell lymphoma
- They do not have constitutively active NF-kappaB activity in their malignant lymph node
- If they are systemically unwell
Summary: Lymphoma is a cancer of white blood cells that occurs commonly in dogs. Chemotherapy is used to treat
lymphoma and about 85% of dogs respond well to this treatment. However, the majority of dogs will relapse with clinical
disease within one year of diagnosis and treatment. One potential reason for disease recurrence is the presence of drug
resistant lymphoma cells that are not killed by chemotherapy. Researchers at Penn Vet have identified an aberrantly
active, intracellular pathway within lymphoma cells that promotes cancer cell survival and proliferation. Results of a pilot
clinical trial have shown that blocking this pathway using a drug known as NBD peptide can promote cancerous cell death.
This clinical trial expands on our previous pilot study and aims to determine whether NBD peptide can inhibit aberrant
pathway activity and kill cancer cells in dogs with B-cell lymphoma improve short and long term outcomes in dogs with
lymphoma.
Benefits: There is no fee to participate in this study. All study procedures (including blood work and lymphoma
immunophenotyping) plus study medication (NBD peptide and antibiotics) will be provided at no cost. The study will pay for
a single dose of standard chemotherapy. The potential benefits could include increased responsiveness to chemotherapy
leading to remission and prolonged remission times in patients receiving the NBD peptide.
WISCONSIN
Study: Dogs with T-cell lymphoma
Location: University of Wisconsin Veterinary Teaching Hospital, Madison, WI
Phone: (608) 263-7600
www.uwveterinarycare.wisc.edu/rdvm/clinical_trials.html
Summary: Lymphoma is one of the most common cancers in dogs. Most affected dogs present with enlarged lymph
nodes. While lymphoma is responsive to chemotherapy, with more than 80% of dogs achieving complete clinical remission
of more than one year, the type of cell involved (T-cell or B-cell) affects prognosis. Dogs with T-cell lymphoma have a
poorer prognosis as these cells are more resistant to chemotherapy and remission times are shorter than for dogs with B-
cell involvement. Recent laboratory observations suggest that the tyrosine kinase inhibitor, masitinib (discussed above
under Malignant Melanoma) may enhance the anti-tumor activity of chemotherapeutic agents. Dogs with confirmed T-cell
lymphoma will be eligible for this study and will be randomized to receive either masitinib alone, doxorubicin alone, or a
combination of these agents. The cost of masitinib and doxorubicin will be paid for by the study. Owners are responsible
for the cost of the initial staging (approximately $400-600), blood and urine tests, and examination fees.
| PET CANCER CENTER Comprehensive guide to cancer diagnosis and treatment in cats and dogs |
© 2007 Pet Cancer Center. ALL RIGHTS RESERVED.
Last updated 1/22/12
Please take our short survey to help us understand pet owners' perception of clinical trials.
| Open clinical trials for dogs |
| Clinical trials for lymphoma in dogs |
Find clinical trials for specific tumor types in dogs:
